Abstract
Background: The management of the Metabolic Syndrome (MetS) includes lifestyle interventions (e.g. diet and exercise for weight reduction), as well as drug treatment to normalize blood pressure, high-density lipoprotein cholesterol, triglycerides and glucose values. Treatment of atherogenic dyslipidemia should comprise a primary therapeutic target since it is associated with an increased risk of cardiovascular disease.
Objective: To review the efficacy of the drugs available for the management of the dyslipidemia associated with MetS.
Methods: MEDLINE was searched up to May 10, 2009 for studies in English using the mesh – terms “metabolic syndrome”, “hypercholesterolemia”, “dyslipidemia”, “treatment”, “statins” and “cardiovascular disease” in various combinations to identify treatment strategies for the management of the dyslipidemia of the MetS.
Results/Conclusions: Several drugs have been described for the management of the dyslipidemia of the MetS, namely statins, fibrates, ezetimibe, niacin, bile acid sequestrants, cholesteryl ester transfer protein inhibitors, as well as combined treatment regimes. Although each of these may deal to some extent with some aspect of the dyslipidemia of the MetS compared with placebo, a direct comparison of all these agents has not been carried out. A head-to-head comparison between the suggested regimes could identify the mono- or combination therapy for the optimal management of dyslipidemia associated with MetS.
Keywords: Metabolic syndrome, dyslipidemia, statins, fibrates, ezetimibe, niacin, bile acid sequestrants
Current Vascular Pharmacology
Title: Targeting Dyslipidemia in the Metabolic Syndrome: An Update
Volume: 8 Issue: 4
Author(s): Kosmas I. Paraskevas, Gabriel Karatzas, Alkisti Pantopoulou, Dimitrios G. Iliopoulos and Despina Perrea
Affiliation:
Keywords: Metabolic syndrome, dyslipidemia, statins, fibrates, ezetimibe, niacin, bile acid sequestrants
Abstract: Background: The management of the Metabolic Syndrome (MetS) includes lifestyle interventions (e.g. diet and exercise for weight reduction), as well as drug treatment to normalize blood pressure, high-density lipoprotein cholesterol, triglycerides and glucose values. Treatment of atherogenic dyslipidemia should comprise a primary therapeutic target since it is associated with an increased risk of cardiovascular disease.
Objective: To review the efficacy of the drugs available for the management of the dyslipidemia associated with MetS.
Methods: MEDLINE was searched up to May 10, 2009 for studies in English using the mesh – terms “metabolic syndrome”, “hypercholesterolemia”, “dyslipidemia”, “treatment”, “statins” and “cardiovascular disease” in various combinations to identify treatment strategies for the management of the dyslipidemia of the MetS.
Results/Conclusions: Several drugs have been described for the management of the dyslipidemia of the MetS, namely statins, fibrates, ezetimibe, niacin, bile acid sequestrants, cholesteryl ester transfer protein inhibitors, as well as combined treatment regimes. Although each of these may deal to some extent with some aspect of the dyslipidemia of the MetS compared with placebo, a direct comparison of all these agents has not been carried out. A head-to-head comparison between the suggested regimes could identify the mono- or combination therapy for the optimal management of dyslipidemia associated with MetS.
Export Options
About this article
Cite this article as:
I. Paraskevas Kosmas, Karatzas Gabriel, Pantopoulou Alkisti, G. Iliopoulos Dimitrios and Perrea Despina, Targeting Dyslipidemia in the Metabolic Syndrome: An Update, Current Vascular Pharmacology 2010; 8 (4) . https://dx.doi.org/10.2174/157016110791330861
DOI https://dx.doi.org/10.2174/157016110791330861 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index to Volume 2
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Dietary Intervention for Allergic Disease
Current Pharmaceutical Design Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Serum Levels of IL-6, TNF-α and IL-10 as Early Predictors of Mortality in Trauma Hemorrhagic Shock Patients
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Optimal Management of Hypertension in patients with Ischemic Heart Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Diabetes Trends in Hospitalized HIV-Infected Persons in the United States, 1994-2004
Current HIV Research ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect
Current Drug Targets Clinical Significance of the New Cardiovascular Risk Markers in Diabetes Mellitus
Current Diabetes Reviews Development of New Fibrinolytic Agents
Current Pharmaceutical Design The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings
Current Vascular Pharmacology A Review of Obesity and Body Fat Distribution and Its Relationship to Cardio-Metabolic Risk in Men and Women of Chinese Origin
Cardiovascular & Hematological Disorders-Drug Targets Transient Receptor Potential (TRP) Cation Channels in Diabetes
Current Topics in Medicinal Chemistry Postconditioning: A New Paradigm for Myocardial Protection?
Current Cardiology Reviews New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs
Current Drug Therapy Current Application of Cyclosporine A to Investigate Skeletal Muscle Adaptation
Current Enzyme Inhibition Transforming Growth Factor β Signaling Perturbation in the Loeys-Dietz Syndrome
Current Medicinal Chemistry Excess Exposure to Insulin Is the Primary Cause of Insulin Resistance and its Associated Atherosclerosis
Current Molecular Pharmacology Transient Secondary Hypothyroidism and Thyroid Hormone Replacement Therapy in Pediatric Postoperative Cardiopulmonary Bypass
Current Cardiology Reviews C-reactive Protein, Infection, and Outcome After Acute Ischemic Stroke: A Registry and Systematic Review
Current Neurovascular Research ATP Non-Competitive Ser/Thr Kinase Inhibitors as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry